At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.
At the 2023 World Congress on...